Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 4/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.57 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.57 |
| ▸ | MYLK | Q15746 | 1/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.49 |
| ▸ | MET | P08581 | 4/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20291125 | 0.88 | MELK (0.73) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20291306 | 0.83 | MET (0.49) | METMEN1KMT2AKDM4EMAPT | |
| SCHEMBL20291307 | 0.82 | LRRK2 (0.45) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20290499 | 0.82 | MELK (0.74) | MELKROCK2METLRRK2ROCK1 | |
| SCHEMBL20291160 | 0.80 | MELK (0.69) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL22837809 | 0.80 | MELK (0.63) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL20291184 | 0.78 | MELK (0.66) | MELKROCK2LRRK2ROCK1 | |
| SCHEMBL20290838 | 0.74 | MELK (0.70) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL23818372 | 0.74 | MELK (1.00) | MELKFLT3CAMK2GCAMK2DMYLK | |
| SCHEMBL29547897 | 0.74 | MELK (1.00) | MELKFLT3CAMK2GCAMK2DMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | MELK, HIPK3, MINK1 | MELK 1/4885FLT3 382/4885CAMK2G 270/4885 |
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | MELK, HIPK3, MINK1 | MELK 1/4885FLT3 382/4885CAMK2G 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.